BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16403097)

  • 1. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial.
    Ooi T; Barnetson RS; Zhuang L; McKane S; Lee JH; Slade HB; Halliday GM
    Br J Dermatol; 2006 Jan; 154(1):72-8. PubMed ID: 16403097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology.
    Szeimies RM; Gerritsen MJ; Gupta G; Ortonne JP; Serresi S; Bichel J; Lee JH; Fox TL; Alomar A
    J Am Acad Dermatol; 2004 Oct; 51(4):547-55. PubMed ID: 15389189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
    Lebwohl M; Dinehart S; Whiting D; Lee PK; Tawfik N; Jorizzo J; Lee JH; Fox TL
    J Am Acad Dermatol; 2004 May; 50(5):714-21. PubMed ID: 15097955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head.
    Alomar A; Bichel J; McRae S
    Br J Dermatol; 2007 Jul; 157(1):133-41. PubMed ID: 17501955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
    Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
    Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.
    Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
    Br J Dermatol; 2007 Dec; 157(6):1132-47. PubMed ID: 17944981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.
    Stockfleth E; Meyer T; Benninghoff B; Salasche S; Papadopoulos L; Ulrich C; Christophers E
    Arch Dermatol; 2002 Nov; 138(11):1498-502. PubMed ID: 12437457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis.
    Persaud AN; Shamuelova E; Sherer D; Lou W; Singer G; Cervera C; Lamba S; Lebwohl MG
    J Am Acad Dermatol; 2002 Oct; 47(4):553-6. PubMed ID: 12271300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.
    Jorizzo J; Dinehart S; Matheson R; Moore JK; Ling M; Fox TL; McRae S; Fielder S; Lee JH
    J Am Acad Dermatol; 2007 Aug; 57(2):265-8. PubMed ID: 17512087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases.
    Ulrich C; Busch JO; Meyer T; Nindl I; Schmook T; Sterry W; Stockfleth E
    Br J Dermatol; 2006 Aug; 155(2):451-4. PubMed ID: 16882188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imiquimod 5% cream for actinic keratosis.
    Perras C
    Issues Emerg Health Technol; 2004 Sep; (61):1-4. PubMed ID: 15382379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
    Gebauer K; Shumack S; Cowen PS
    Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imiquimod for actinic keratosis: systematic review and meta-analysis.
    Hadley G; Derry S; Moore RA
    J Invest Dermatol; 2006 Jun; 126(6):1251-5. PubMed ID: 16557235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.
    Lee PK; Harwell WB; Loven KH; Phillips TJ; Whiting DA; Andres KL; Lee JH
    Dermatol Surg; 2005 Jun; 31(6):659-64. PubMed ID: 15996416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
    Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
    J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.
    Geisse J; Caro I; Lindholm J; Golitz L; Stampone P; Owens M
    J Am Acad Dermatol; 2004 May; 50(5):722-33. PubMed ID: 15097956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.
    Ulrich C; Bichel J; Euvrard S; Guidi B; Proby CM; van de Kerkhof PC; Amerio P; Rønnevig J; Slade HB; Stockfleth E
    Br J Dermatol; 2007 Dec; 157 Suppl 2(Suppl 2):25-31. PubMed ID: 18067628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is imiquimod effective and safe for actinic keratosis?
    Walker JK; Koenig C
    J Fam Pract; 2003 Mar; 52(3):184-5. PubMed ID: 12620165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.